In this role, Nrf2 activity has been shown to be an important disease modifier in many oxidative/inflammatory diseases, such as asthma, sepsis, and pulmonary fibrosis, in which decreased Nrf2 activity exacerbates disease progression [14-16]. This evidence concerns the gene NFE2L2 and pulmonary fibrosis.